Could probióticos be proposed as an optional treatment for IBD?

R. CURCIARELLO; K. CANZIANI; I. SALTO; M. SERRADELL; A. ERREA; M. RUMBO; A. HUGO; A. ROCCA; S. BRAYER; A. SAMBUELLI; M. YANTORNO ; G. CORREA; L. GARBI ; G. DOCENA; C. MUGLIA

Mar del Plata

Congreso; Reunion Conjunta SAIC SAI SAFIS 2018- LXVI Reunión Anual de la Sociedad Argentina de Inmunología; 2018

Sociedad Argentina de Inmunología

Inflammatory bowel diseases (IBD) are a group of disorders, including the most conspicuous ones ulcerative colitis (UC) and Crohn´s disease (CD), which are characterized by chronic and relapsing inflammation of the gastrointestinal tract. Affected individuals suffer from debilitating symptoms with severe complications, and a higher risk of colorectal cancer. The frequency of IBD is increasing worldwide, seriously affecting health care costs and inbreeding hospital beds. Over the last decades great effort has been dedicated to understanding the pathogenesis of these inflammatory disorders. It is known that lamina propria T cells (LPTC) play a central role in these pathologies, through the secretion of pro-inflammatory cytokines along with a defective apoptosis. Although novel therapeutic options have arisen there is no effective therapy for most patients. Furthermore, responder patients may become non-responder during treatment. For these reasons there is a need for novel therapeutical strategies. Kefir is a fermented milk with health-promoting properties that has been used as treatment for gastrointestinal disorders since ancient times. In our group we have established a method for developing microbe-specific T cell lines from LPTC of IBD patients. We showed that microorganisms from kefir (Enterococcus durans and Lactobacillus kefiri) or their conditioned media modulated anti-CD3-/anti-CD28- induced proliferation and secretion of pro-inflammatory cytokines. In addition, we found that these probiotics suppressed NFKB activation.In conclusion, we found that probiotic strains from kefir and their metabolites can modulate pathogen-specific activated T cells from IBD patients. These findings may pave the way for novel therapeutic options for patients with IBD.